Journal: Genes and immunity

Article Title: Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.

doi: 10.1038/gene.2009.72

Figure Lengend Snippet: Figure 4 Peripheral blood mononuclear cells (PBMCs), keratino- cytes and HepG2 cells express interferon (IFN)-lR1 and IL-10R2 protein. Protein expressions of IFN-l receptor components and of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were analyzed in the cell lysates of PBMCs from three donors as well as of keratinocytes and HepG2 cells using the western blot technique.

Article Snippet: For the detection of IFN-l receptor components, we incubated blots with anti-IFNlR1 pAbs (50 ng ml 1; Sigma-Aldrich), anti-IL-10R2 pAbs (600 ng ml 1; R&D Systems) and anti-GAPDH mAb (200 ng ml 1; clone 6C5; Millipore), followed by peroxidase-conjugated AffiniPure goat anti-rabbit IgG (H and L), rabbit anti-goat IgG (H and L) and goat antimouse IgG (H and L) (all from Dianova) incubation, respectively, and final ECL detection.

Techniques: Western Blot

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Systemic Antibiotic Therapy Reduces Circulating Inflammatory Dendritic Cells and Treg-Th17 Plasticity in Periodontitis.

doi: 10.4049/jimmunol.1900046

Figure Lengend Snippet: Increased expression of IL-1R1 and IL-6Rα in CD4+Foxp3+ T cells in PD patients. CD4+ T cells were stimulated as in figure 3 in the presence and absence of IL-1β+IL-6. (A and B) Frequencies of C4+Foxp3+ T cells expressing IL-1R1 was increased in non-AB (n = 6–9) patients compared to healthy controls (HC) (n = 8) and AB (n = 5–6) subjects at day6 (A) and final (B) time points (Data are mean ± SEM, *p<0.05, **p<0.01, ***p<0.001). (C and D) Graphs depicts the Spearman’s positive correlation of Foxp3+IL-1R1+ population with %IL17A+Foxp3+ T cells (C) and Th17 cells (D) at final time point in response to IL1-β and IL-6 in non-AB group (n=6). (E and F) Graph shows the percentage of C4+Foxp3+ T cells expressing IL6Rα in healthy controls (HC) (n = 8), non-AB (n = 6–9), and AB (n = 5–6) subjects at day6 (E) and final (F) time points (Data are mean ± SEM, *p<0.05, **p<0.01). (G) Graph depicts the Spearman’s positive correlation between the Foxp3+IL-6Rα+ population and %IL17A+Foxp3+ T cells at final time point in response to IL1-β and IL-6 in non-AB group (n=9). (H) Increased expression of IL-1R1 in IL-17A+Foxp3+ Treg compared to conventional Treg and Th17 populations in periodontitis (PD) patients (Data are mean ± SEM, *p<0.05, **p<0.01, ***p<0.001). (I) Increased expression of IL-6Rα in IL-17A+Foxp3+ Treg compared to conventional IL17A-Foxp3+ Treg (Data are mean ± SEM, *p<0.05).

Article Snippet: Conjugated antibodies against the following were from R&D systems: RORγT (clone AFKJS-9) and IL-1R1 (Catalog number FAB269F).

Techniques: Expressing

Journal: Oncology reports

Article Title: Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease.

doi: 10.3892/or.2015.4176

Figure Lengend Snippet: Figure 1. Anti-IL-18Rα mAb alleviates aGVHD systemic symptoms in aGVHD mice. aGVHD was induced in irradiated BALB/c mice by BMC transplanta- tion. Ten micrograms of anti-IL-18Rα mAb was administered by intraperitoneal injection to mice in the BS+Ab group, while the BS group received injection of PBS. (A) Hunch posture, hair loss and skin lesions were evaluated on day 14 P.T. (B) Changes in body weight of the recipient mice at different time‑points in the different groups. (C) aGVHD clinical scores of the BS+Ab and BS groups on day 14 P.T. (D) Survival rates of aGVHD mice in the different groups. n=6 in each group. *P<0.05. GVHD, graft-versus-host disease; IL-18, interleukin-18; aGVHD, acute GVHD; BMC, bone marrow cell; PBS, phosphate-buffered solution; mAb, monoclonal antibody; P.T., post‑transplantation.

Article Snippet: Recipient mice in the BS+Ab group also received 10 μg/mouse intraperitoneal injection of neutralizing mAb against murine IL-18Rα (catalog no. MAB12161; R&D Systems, Minneapolis, MN, uSA) every 2 days.

Techniques: Irradiation, Injection

Journal: Oncology reports

Article Title: Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease.

doi: 10.3892/or.2015.4176

Figure Lengend Snippet: Figure 2. Effect of anti-IL-18Rα mAb administration on Th cell subsets, pro-inflammatory cytokines and histological scores in the aGVHD mice. (A-C) Peripheral blood levels of Th1 (A), Th2 (B) and Th17 (C) cell subsets in the BS+Ab and BS experimental groups were measured by flow cytometry at different time-points. Serum levels of IFN-γ (D), IL-4 (E), IL-17A (F) and IL-6 (H) at different time-points were detected by cytometric bead array, and IL-18 levels (G) were measured by ELISA. (I) Representative H&E staining of the liver and small intestine tissues of the mice in the BS+Ab and BS groups and the normal control group (untreated animals) on day 14 P.T. Magnification, x400. (J) Histological score was measured on day 14 P.T. n=6 in each group, *P<0.05. GVHD, graft-versus-host disease; aGVHD, acute GVHD; mAb, monoclonal antibody; Th, T helper; IL-18, interleukin-18; ELISA, enzyme-linked immunosorbent assay; H&E, hematoxylin and eosin; P.T., post‑transplantation.

Article Snippet: Recipient mice in the BS+Ab group also received 10 μg/mouse intraperitoneal injection of neutralizing mAb against murine IL-18Rα (catalog no. MAB12161; R&D Systems, Minneapolis, MN, uSA) every 2 days.

Techniques: Flow Cytometry, Enzyme-linked Immunosorbent Assay, Staining, Control